AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 301 min read$ASPE

Aspen Neuroscience Prices $140.6 Mln IPO At $15/shr

Aspen Neuroscience priced its IPO at $15 per share, raising $140.6 million. The offering includes 9.375 million shares, with an option for 1.406 million more. Trading begins on Nasdaq under ASPE on October 30.

Original reporting
rttnews.com
Published Oct 30, 2026, 6:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Aspen Neuroscience Prices $140.6 Mln IPO At $15/shr — source image
Source · rttnews.com
Decision brief

The 30-second read

$ASPEBullishHigh
01

Why it matters

The pricing of the IPO at $15 per share raises $140.6M, providing capital for development and signaling market appetite for biotech offerings.

02

Market read

The new $140M biotech IPO adds liquidity to the sector and may influence investor sentiment toward similar early‑stage companies.

03

What to watch

Regulatory approval timelines and trial outcomes could materially affect post‑IPO performance.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

Aspen Neuroscience is a clinical‑stage regenerative medicine biotechnology company planning to list on Nasdaq.

Company-level read

Ticker impact

$ASPEBullishHigh confidence
Context

Aspen Neuroscience announced pricing its IPO at $15 per share, generating $140.6M in gross proceeds.

Expected impact

likely upward pressure as investors seek allocation to the new issue

Evidence & confidence

First report of a $140M biotech IPO at a clear price point indicates market interest and potential price appreciation at debut.

Market effects

Sector

Adds fresh capital to the biotech sector and may spur further regenerative‑medicine IPO activity.

Regional

Impacts US Nasdaq listings and biotech investor sentiment.

Global

Highlights growing global interest in clinical‑stage regenerative medicine companies.

Counterpoint

What could challenge this read

The IPO could be over‑priced; market may be cautious given early‑stage clinical risk.

Key entities

  • company
    Aspen Neuroscience

    Clinical‑stage regenerative medicine biotech filing for IPO on Nasdaq.

Read at source← All news

StoryAspen Neuroscience prices Parkinson’s cell-therapy IPO

Also covered by

5 outlets

Related articles

OCT 30
$ASPEHighAI 9/10

Aspen raises a $140M IPO in pursuit of a cell therapy for Parkinson’s

Aspen Neuroscience raised $140.6M in its IPO, selling 9.4M shares at $15 each. The company's cell therapy, sasineprocel, aims to treat Parkinson's by replenishing dopamine-producing neurons. It will trade under 'ASPE'. Early trial data showed potential improvements and a favorable safety profile. Long-term data is expected in 2028, with a Phase 3 study planned by the end of 2024. Aspen claims its personalized approach could be safer and more effective than donor-derived therapies.

finance.yahoo.com2 min
OCT 30
$ASPEHighAI 9/10

Aspen Neuroscience prices IPO at $15 per share

Aspen Neuroscience (ASPE) priced its IPO at $15 per share, offering 9.375 million shares for gross proceeds of $140.6 million. The biotech company focuses on Parkinson's disease treatments. Shares began trading on Nasdaq under ASPE. Underwriters have a 30-day option for additional shares. The offering is expected to close November 2, 2026.

investing.com1 min
OCT 30
$ASPEHighAI 8/10

A Parkinson’s cell-therapy company expects about $140.6 million from its share sale, before costs.

Aspen Neuroscience, Inc. (Nasdaq: ASPE) announced its initial public offering of 9,375,000 shares at $14.95 per share, expected to raise $140.6 million before costs. Trading is set to begin on October 30, 2026, under the ticker ASPE. The offering is expected to close on November 2, 2026. The company focuses on developing autologous cell therapies for Parkinson's disease.

stocktitan.net2 min